CatherineBollardMD

PubMed

• 6 citations
  Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
  Stephanie Gomez, Olivia L Cox, Reddick R Walker 3rd, Uzma Rentia, Melissa Hadley, Elisa Arthofer, Noor Diab, Erin E Grundy, Tomas Kanholm, James I McDonald, Julie Koby...> ;Journal for Immunotherapy of Cancer. 2022 Nov 1
• 2 citations
  Interstitial Photothermal Therapy Generates Durable Treatment Responses in Neuroblastoma.
  Debbie K Ledezma, Preethi B Balakrishnan, Anshi Shukla, Jacob A Medina, Jie Chen, Emily Oakley, Catherine M Bollard, Gal Shafirstein, Mario Miscuglio, Rohan Fernandes> ;Advanced Healthcare Materials. 2022 Oct 1
• Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel.
  Oren M Gordon, Madeline Terpilowski, Robin Dulman, Michael D Keller, Peter D Burbelo, Jeffrey I Cohen, Catherine M Bollard, Hema Dave> ;Pediatric Hematology and Oncology. 2022 Sep 1
• 40 citations
  Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
  David T Teachey, Meenakshi Devidas, Brent L Wood, Zhiguo Chen, Robert J Hayashi, Michelle L Hermiston, Robert D Annett, J Hunter Archer, Barbara L Asselin, Keith J Aug...> ;Journal of Clinical Oncology. 2022 Jul 1
• 11 citations
  Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia.
  Scott Raskin, Stacey Van Pelt, Keri Toner, Preethi Bala Balakrishnan, Hema Dave, Catherine M. Bollard, Eric Yvon> ;Molecular Therapy. Methods & Clinical Development. 2021 Dec 10
• 22 citations
  Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
  Samuel Rivero-Hinojosa, Melanie Grant, Aswini Panigrahi, Huizhen Zhang, Veronika Caisova, Catherine M. Bollard, Brian R. Rood> ;Nature Communications. 2021 Nov 18
• 10 citations
  Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients.
  Jeremy D. Rubinstein, Sonata Jodele, Daria Heyenbruch, Jamie Wilhelm, Shawn Thomas, Carolyn Lutzko, Xiang Zhu, Thomas Leemhuis, Jose A. Cancelas, Michael D. Keller, Ca...> ;Transplantation and Cellular Therapy. 2021 Nov 13
• 1 citations
  Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort.
  Conrad Russell Y. Cruz, Na Bo, Giorgos Bakoyannis, Kaylor E. Wright, Elizabeth Chorvinsky, Allison B. Powell, Catherine M. Bollard, David A. Jacobsohn, Kenneth R. Cook...> ;Bone Marrow Transplantation. 2021 Oct 28
• 9 citations
  High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia.
  Blachy J. Dávila Saldaña, Tami D John, Challice L. Bonifant, David Buchbinder, Sharat Chandra, Shanmuganathan Chandrakasan, Weni Chang, Leon Chen, Hannah L Elfassy, As...> ;Blood Advances. 2021 Oct 20
• 12 citations
  Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal ...
  G. A. Amos Burke, Veronique Minard-Colin, A. Auperin, Sarah Alexander, Marta Pillon, Rafael Delgado, Jozsef Zsiros, Anne Uyttebroeck, Peggy Dartigues, Rodney R. Miles,...> ;Journal of Clinical Oncology. 2021 Sep 27
• 1 citations
  Using Molecular Stratification for Smart Combination Therapies.
  Amy B. Hont, Catherine M. Bollard> ;Journal of Clinical Oncology. 2021 Sep 24
• 21 citations
  Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
  Jeremy D. Rubinstein, Xiang Zhu, Thomas Leemhuis, Giang Pham, Lorraine Ray, Sana Emberesh, Sonata Jodele, Shawn Thomas, Jose A. Cancelas, Catherine M. Bollard, Patrick...> ;Blood Advances. 2021 Sep 14
• 8 citations
  Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma.
  Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher A. Lazarski, Abeer Shibli, Stephanie Ann Bien, Philp Maglo, Fahmida ...> ;Blood Advances. 2021 Sep 8
• 5 citations
  Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains.
  Maja Stanojevic, Ashley Geiger, Brita Ostermeier, Danielle Sohai, Christopher A. Lazarski, Haili Lang, Mariah Jensen-Wachspress, Kathleen Webber, Peter D. Burbelo, Jef...> ;Cytotherapy. 2021 Sep 2
• 11 citations
  EBV+ Lymphoproliferative Diseases: Opportunities for leveraging EBV as a Therapeutic Target.
  Keri Toner, Catherine M. Bollard> ;Blood. 2021 Aug 26
• 2 citations
  Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma.
  Xinjie Xu, Christian N. Paxton, Robert J. Hayashi, Kimberly P. Dunsmore, Stuart S. Winter, Stephen P. Hunger, Naomi J. Winick, William L. Carroll, Mignon L. Loh, Meena...> ;Blood Advances. 2021 Jul 27
• 10 citations
  Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
  Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Ch...> ;Annals of Hematology. 2021 Jul 24
• Introduction to a review series on gene therapy and gene editing for sickle cell disease and hemophilia.
  Catherine M. Bollard> ;Blood. 2021 Sep 16
• 8 citations
  A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies.
  Chase D. McCann, Christiaan H. van Dorp, Ali Danesh, Adam R. Ward, Thomas R Dilling, Talia M. Mota, Elizabeth Zale, Eva M. Stevenson, Shabnum Patel, Chanson J. Brumme,...> ;The Journal of Experimental Medicine. 2021 Jul 5
• 3 citations
  Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures.
  Christopher A. Lazarski, Keri Toner, Michael D. Keller, Naomi L.C. Luban, Pampee P. Young, Catherine M. Bollard, Stephen J. Wagner, Patrick J. Hanley> ;Blood Transfusion = Trasfusione Del Sangue. 2021 Jun 14
• 43 citations
  Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
  Hannah Kinoshita, Jessica Durkee-Shock, Mariah Jensen-Wachspress, Vaishnavi V. Kankate, Haili Lang, Christopher A. Lazarski, Anjeni Keswani, Kathleen Webber, Kimberly ...> ;Journal of Clinical Immunology. 2021 Jan 1
• 3 citations
  Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
  Kajal Chaudhry, Ehsan Dowlati, Catherine M. Bollard> ;Expert Review of Clinical Immunology. 2021 Apr 12
• 4 citations
  Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell thera...
  Maja Stanojevic, Amy B. Hont, Ashley Geiger, Samuel O'Brien, Robert Ulrey, Melanie Grant, Anushree Datar, Ping-Hsien Lee, Haili Lang, Conrad Russell Y. Cruz, Patrick J...> ;Cytotherapy. 2021 Apr 5
• 39 citations
  Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
  Eric J. Lowe, Anne Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig, Donald A. Barkauskas, Rui Wu, Sarah Alexander, Catherine M. Bollard> ;Blood. 2021 Jul 1
• 21 citations
  T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
  Spyridoula Vasileiou, Premal Lulla, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Wendy L Callejas, Mrinalini Bilgi, Tao Wang, Mengfen J Wu, Rammurti T. Kamble, ...> ;Journal of Clinical Oncology. 2021 Jan 28
• Join now to see all

Journal Articles

• Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy  
  Kris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature
• EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation  
  Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
• Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204  
  Shalini Shenoy, K Scott Baker, Elizabeth O Stenger, Mary Eapen, Carl Allen, Lauri Burroughs, Philip Roehrs, Catherine M Bollard, Rabi Hanna, Jeffrey R Andolina, James ..., Blood
• Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells  
  Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM, Mol Ther., 1/30/2014
• Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antivira...  
  Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K,..., Clin Cancer Res., 1/25/2014
• Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?  
  Lankester AC, Locatelli F, Bader P, Rettinger E, Egeler M, Katewa S, Pulsipher MA, Nierkens S, Schultz K, Handgretinger R, Grupp SA, Boelens JJ, Bollard CM, Biol Blood Marrow Transplant., 1/23/2014
• Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future  
  Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ, Stem Cells Transl Med., 1/5/2014
• Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: Implications for immunotherapy  
  Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, Kuruc J, Archin N, Rooney C, Margolis D, Bollard C, Mol Ther., 1/4/2014
• Sustained Complete Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes (CTL) Targeting Epstein-BarrVirus Latent Membrane Proteins  
  CM Bollard, S Gottschalk, V Torrano, O Diouf, S Ku, Y Hazrat, G Carrum, C Ramos, L Fayad, EJ. Shpall, B Pro, H Liu, MF Wu, D Lee, AM Sheehan, Y Zu, AP Gee, MK Brenner..., J Clin Oncol., 1/1/2014
• Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers  
  Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xie Z, Marincola F, Tanimoto K, Battiwalla M, Olnes MJ, Perl S, Schum..., Mol Ther, 1/1/2014
• Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity  
  Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM, J Immunother., 1/1/2014
• Immunotherapy: opportunities, risks and future perspectives (Review)  
  Hildebrandt M, Peggs K, Uharek L, Bollard CM, Heslop HE, Cytotherapy, 1/1/2014
• Reply to S Yuan et al  
  Bollard CM, Heslop HE, Rooney CM, J Clin Oncol., 1/1/2014
• A change in the editorial office: farewell from Catherine M Bollard  
  Bollard CM, Pediatr Hematol Oncol., 1/1/2014
• The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  
  Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L..., Clin Lymphoma Myeloma Leuk., 1/26/2013
• Challenges and Opportunities for International Cooperative Studies in Pediatric Hematopoeitic Cell Transplantation: Priorities of the Westhafen Intercontinental Group  
  Schultz KR, Baker KS, Boelens JJ, Bollard CM, Egeler RM, Cowan M, Ladenstein R, Lankester A, Locatelli F, Lawitschka A, Levine JE, Loh M, Nemecek E, Niemeyer C, Prasad..., Biol Blood Marrow Transplant, 1/21/2013
• Scouting out the neighborhood in AIDS-related lymphoma  
  Dunleavy K, Bollard CM, Blood, 1/18/2013
• The effects of age and latent cytomegalovirus infection on the redeployment of CD8+ T cell subsets in response to acute exercise in humans  
  Spielmann G, Bollard CM, Bigley AB, Hanley PJ, Blaney JW, Lavoy EC, Pircher H, Simpson RJ, Brain Behav Immun., 1/15/2013
• Robust T Cell Responses to Aspergillosis in Chronic Granulomatous Disease: Implications for Immunotherapy  
  Cruz CR, Lam S, Hanley PJ, Bear AS, Langston C, Cohen AJ, Liu H, Martinez CA, Krance RA, Heslop HE, Rooney CM, Hanson IC, Bollard CM, Clin Exp Immunol., 1/13/2013
• Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells  
  Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ, Brain Behav Immun., 1/5/2013
• Pediatric Burkitt's Lymphoma and Diffuse B-Cell Lymphoma: Are Surveillance Scans Required?  
  Eissa HM, Allen CE, Kamdar K, Simko S, Goradia P, Dreyer Z, Steuber P, McClain KL, Guillerman RP, Bollard CM, Pediatr Hematol Oncol., 1/2/2013
• Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia - implications for immunotherapy  
  Weber G, Caruana I, Rouce RH, Barrett J, Leen AM, Rabin KR, Bollard CM, Clin Cancer Res., 1/1/2013
• Children's Oncology Group's 2013 blueprint for research: Non-Hodgkin lymphoma  
  Bollard CM, Lim MS, Gross TG; COG Non-Hodgkin Lymphoma Committee, Pediatr Blood Cancer, 1/1/2013
• Highlights of the third international conference on immunotherapy in pediatric oncology  
  Brehm C, Huenecke S, Pfirrmann V, Rossig C, Mackall CL, Bollard CM, Gottschalk S, Schlegel PG, Klingebiel T, Bader P, Pediatr Hematol Oncol., 1/1/2013
• Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients  
  Wistinghausen B, Gross TG, Bollard C, Pediatr Hematol Oncol., 1/1/2013
• Join now to see all

Books/Book Chapters

• Targeted Therapy of Acute Myeloid Leukemia 
  Chapter: Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias. 
  G Weber, CM Bollard, AJ BarrettEditors: Andreeff.Springer2014
• Principles & Practice of Pediatric Oncology 
  Chapter: Pediatric Hematopoietic Stem Cell Transplantation. 
  S Gottschalk, S Naik, M Hegde, CM Bollard, RA Krance and HE HeslopEditors: Pizzo and Poplack.Lippincott Williams & WilkinsEdition 6th,2014
• Principles & Practice of Pediatric Oncology 
  Chapter: Malignant Non-Hodgkin Lymphomas in Children. 
  CE Allen, K Kamdar, CM Bollard, T GrossEditors: Pizzo and Poplack.Lippincott Williams & WilkinsEdition 6th,2014
• Hematology, Principles and Practice 
  Chapter: Pediatric Lymphomas. 
  Kamdar K, Sandlund J, Bollard CMEditors: Hoffman.Elsevier2012
• Hematology, Principles and Practice 
  Chapter: Normal Blood Values: Selected Reference Values For Neonatal, Pediatric, And Adult Populations. 
  Yee D, Bollard CM, Geaghan, SMEditors: Hoffman.Elsevier2009
• Rossi’s Principles of Transfusion Medicine 
  Chapter: Adoptive Immunotherapy. 
  Bollard CM and Heslop HEEditors: Snyder.Edition 4th,2009
• The Lymphoid Neoplasms 
  Chapter: Cellular Therapies For Lymphoma. 
  Bollard CM, Rooney CM, Heslop HEEditors: Ian McGrath.Edition 3rd,2008
• TGFB in Cancer Therapy 
  Chapter: Role of TGFB in Tumor Protection and Anti-tumor Immunity. 
  Bollard CM, Rooney CMEditors: Jakowlew.Humana Press2007
• Immunotherapy and Gene Therapy in Hematological malignancies 
  Chapter: Disease-Based Application – Hodgkin Disease: Immune Status. 
  Kennedy-Nasser, A and Bollard CMEditors: Munshi, Gribben, and Heslop.Springer Science2007
• Principles & Practice of Pediatric Oncology 
  Chapter: Pediatric Bone Marrow Transplantation. 
  Bollard CM, Krance RA, Heslop HEEditors: Pizzo and Poplack.Lippincott Williams & WilkinsEdition 4th,2006
• Human Herpesvirus 
  Chapter: Adoptive Immunotherapy for herpesviruses. 
  AM. Leen, U Sili, CM Bollard, CM. RooneyCambridge University Press2006
• Hematology, Principles and Practice 
  Chapter: Graft Engineering to Enhance Engraftment, Reduce Graft-versus-Host Disease and Provide a Graft versus-Tumor Effect. 
  Bollard CM, Gee APEditors: Hoffman.Elsevier2004
• Gene Therapy: Therapeutic Mechanisms and Strategies 
  Chapter: Gene Marking of Hematopoietic cells. 
  Bollard CM, Brenner MK, Heslop HEEditors: N. Smyth-Templeton.Edition 2nd,2003
• Clinical Bone Marrow and Blood Stem Cell Transplantation 
  Chapter: Post Transplant Lymphoproliferative Disease. 
  Bollard CM, Rooney CM, Heslop HEEditors: Atkinson, Fibbe, Champlin, Ljungman, Ritz and Brenner.Cambridge UniversityEdition 3rd,2003
• Pediatric Allergy: Principles & Practice 
  Chapter: Gene Therapy and Allergy. 
  Bollard CM and Brenner MKEditors: Leung DYM.Elsevier ScienceEdition 1st,2002
• Join now to see all

Abstracts/Posters

• Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH
  Catherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identifying Novel Immunodominant Epitopes within Human Parainfluenza Virus-3 Matrix Protein
  Catherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ultra low-dose il-2 mediated expansion of regulatory T cells as GVHD prophylaxis for recipients of allogeneic hematopoietic stem cells blood transplantation.
  Catherine Bollard 1,*,Alana Kennedy-Nasser 2,A. John Barrett 3,Sawa Ito 3,Eric Yvon 4,Robert Krance 2,Kathryn Leung 2,Helen E. Heslop 2,Malcolm K. Brenner2, Poster Presentation, EBMT; Bone Marrow Transplant, Milan, Italy, 1/31/2014
• Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-B to Treat Patients with EBV-Associated Lymphomas.
  CM. Bollard, G Dotti, S Gottschalk, E Liu, A Sheehan, M Mims, H Liu, AP. Gee, MK. Brenner, HE. Heslop, CM Rooney, Oral Session: ISCT – North American Meeting, 1/1/2013
• Infusion Of Donor-Derived CD19-Redirected-Virus-Specific T Cells For B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase I Study. Oral Sessions...
  Conrad Russell Y. Cruz, Kenneth P. Micklethwaite, Barbara Savoldo, Carlos A. Ramos, Sharon Lam, Stephanie Ku, Oumar Diouf, Enli Liu, A. John Barrett, Sawa Ito, Elizabe..., Blood, 1/1/2013
• Ex Vivo Expanded Multi-Specific Cytotoxic T Lymphocytes Derived From HIV+ Patients and HIV Negative Donors Using GMP Compliant Methodologies Recognize Multiple HIV Ant...
  Sharon Lam, Julia Marsh Sung, Conrad RY Cruz, Paul Castillo-Caro, Minh T. Ngo, Carolina Garrido, Joann Kuruc, Cliona M. Rooney, David Margolis, and Catherine M. Bollard, Blood, 1/1/2013
• Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation.Oral Sessions - 703. Adoptive Immunotherapy.
  Patrick Hanley, Ann Leen, Adrian P. Gee, Kathryn Leung, Caridad Martinez, Robert A. Krance, Hao Liu, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, and Catheri..., Blood, 1/1/2013
• Donor T Cells Specific for Multiple Leukemia Antigens for Adoptive Immunotherapy of Myeloid Leukemias after Stem Cell Transplantation.
  John A. Barrett, Gerrit Weber, Ulrike Gerdemann, Sid Kerkar, Pawel Muranski, Nancy F. Hensel, Ann Leen, Jos J. Melenhorst, Cath M. Bollard, Oral presentation, ASGCT, Molecular Therapy, Philadelphia, PA, 1/19/2012
• Infusion of CD19-Directed/Multivirus-Specific CTLs Post HSCT for B Cell Malignancies.
  Conrad Cruz, Kenneth Micklethwaite, Barbara Savoldo, Stephanie Ku, Robert Krance, Oumar Diouf, Rammurti Kamble, Alana Kennedy-Nasser, John Barrett, Elizabeth Shpall, H..., Oral presentation, ASGCT; Molecular Therapy, Philadelphia, PA, 1/19/2012
• Phase I Study To Improve Virus-Specific Immune Reconstitution after Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific T Cells.
  Patrick J. Hanley, Caridad A. Martinez, Barbara Savoldo, Gianpietro Dotti, Malcolm K. Brenner, Cliona Rooney, Helen E. Heslop, Robert A. Krance, Elizabeth J. Shpall, C..., Oral presentation, ASGCT, Molecular Therapy, Philadelphia, PA, 1/18/2012
• Administration of TGFB-Resistant Tumor-Specific Cytotoxic T Lymphocytes (CTL) to Patients with EBV-Associated Hodgkin's Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL).
  Catherine M. Bollard, Gianpietro Dotti, Stephen Gottschalk, Martha Mims, Hao Liu, Adrian P. Gee, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, Oral presentation, ASGCT; Molecular Therapy, Philadelphia, PA, 1/17/2012
• Outcomes of CD19-directed multivirus specific cytotoxic T lymphocyte therapy for patients with relapsed B cell malignancies after allogeneic hematopoietic stem cell tr...
  Catherine Bollard , Conrad Cruz, Barbara Savoldo, Robert Krance, Ram Kamble, A. John Barrett, Chitra Hosing, Elizabeth Shpall, Helen Heslop, Ann Leen, Cliona Rooney, M..., Oral presentation, abstract 877 EBMT; Bone Marrow Transplantation, Geneva, Switzerland, 1/3/2012
• Administration Of Cord Blood (CB)-Derived Virus-specific Cytotoxic T Lymphocytes to Prevent CMV, Adenovirus, and EBV infection after CB Transplant.
  Patrick Hanley, Caridad Martinez, Jan Melenhorst, Kathryn Leung, Barbara Savoldo, Ann Leen, Gianpietro Dotti, Adrian Gee, Cliona Rooney, Helen Heslop, Robert Krance, A..., Oral presentation, abstract 886. EBMT; Bone Marrow Transplantation, Geneva, Switzerland, 1/3/2012
• The Clinical Use of Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus, and Epstein-Barr Virus (EBV).
  P. Hanley, B. Savoldo, C.R. Cruz, A.M. Leen, J. Rodgers, H. Liu, A.P. Gee, H.E. Heslop, C.M. Rooney, M.K. Brenner, E.J. Shpall, C.M. Bollard, Biology of Blood and Marrow Transplantation, 1/1/2011
• NaïVe T Cells From Cord Blood and CMV-Seronegative Donors Recognize Atypical Epitopes of Cmvpp65 and Can Be Used for Adoptive Immunotherapy.
  P.J. Hanley, S. Lam, C.R.Y. Cruz, B. Savoldo, T. Benjamin, K. Stephanie, D. Lilleri, G. Gerna, G. Demmler-Harrison, G. Dotti, H.E. Heslop, M.K. Brenner, C.M. Rooney, E..., Biology of Blood and Marrow Transplantation, 1/1/2011
• Combined Epigenetic and Immune-Based Therapies for Relapsed Hodgkin'S Lymphoma Post Hematopoietic Stem Cell Transplant.
  C.R.Y. Cruz, U. Gerdemann, J.A. Shafer, A.M. Leen, C.M. Rooney, A. Younes, T.M. Horton, H.E. Heslop, C.M. Bollard, Biology of Blood and Marrow Transplantation, 1/1/2011
• Immune Reconstitution and Infectious Complications in Cord Blood Transplant Patients.
  A.M. Leen, R. Saliba, I. Maewal, S. Ku, U. Katari, T. Tripic, M. de Lima, A. Alousi, E.J. Shpall, C.M. Bollard, Biology of Blood and Marrow Transplantation, 1/1/2011
• Immediate Adverse Events Following infusion of ex vivo-Expanded Cord Blood for Stem Cell Transplantation.
  A.S. Bear, P.J. Hanley, D.M. Bosque, M.J. de Lima, P. Kebriaei, C. Hosing, H.E. Heslop, C.M. Bollard, Biology of Blood and Marrow Transplantation, 1/1/2011
• Expansion of T Cells Targeting Multiple Antigens of CMV, EBV, and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation.
  P.J. Hanley, D.R. Shaffer, C.R.Y. Cruz, S. Ku, B. Tzou, G. Demmler-Harrison, C.M. Rooney, H.E. Heslop, S.M. Gottschalk, C.M. Bollard, Biology of Blood and Marrow Transplantation, 1/1/2011
• Multi-virus-specific T-cell therapy for patients after haematopoietic stem cell transplantation.
  C.M. Bollard, A.M. Leen, R.A. Krance, K. Leung, A.P. Gee, M.K. Brenner, H.E. Heslop, C.M. Rooney, Presidential Symposium, EBMT; Bone Marrow Transplant, Paris, France, Apr 4, 2011, 1/1/2011
• Cord blood-derived virus-specific cytotoxic T-lymphocyte therapy for cytomegalovirus, adenovirus, and Epstein-Barr virus.
  C.M. Bollard, P. Hanley, C. Martinez, K. Leung, C.R.Y. Cruz, R.A. Krance, A.P. Gee, H. Liu, H.E. Heslop, C.M. Rooney, E.J. Shpall, Presidential Symposium, EBMT; Bone Marrow Transplant, Paris, France, Apr 4, 2011, 1/1/2011
• LMP-specific cytotoxic T-lymphocytes administered to EBV+ lymphoma patients after stem cell transplant.
  C.M. Bollard, S. Gottschalk, A. Sheehan, M. Mims, G. Carrum, H. Liu, A.P. Gee, M.K. Brenner, C.M. Rooney, H.E. Heslop, Oral presentation, EBMT; Bone Marrow Transplant, Paris, France, Apr 4, 2011, 1/1/2011
• Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins.
  Catherine M. Bollard, Stephen Gottschalk, Andrea M. Sheehan, George Carrum, Hao Liu, Barbara Pro, Luis Fayad, Anas Younes, Martha Mims, Adrian P. Gee, Malcolm K. Brenn..., Blood (ASH Annual Meeting Abstracts), 1/1/2011
• Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes.
  Patrick J Hanley, Caridad Martinez, Kathryn Leung, Barbara Savaldo, Gianpietro Dotti, Adrian P. Gee, Cliona M. Rooney, Helen E. Heslop, Robert A. Krance, Elizabeth J S..., Blood (ASH Annual Meeting Abstracts), 1/1/2011
• Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4.
  Conrad Russell Y. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Amanda Copeland, Anas Younes, Cliona M. Rooney..., Blood (ASH Annual Meeting Abstracts), 1/1/2011
• Join now to see all

Lectures

• Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Meet the Blood Editors 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Meet the Blood Editors 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• The Landscape of Anti-CD-19 CAR-T Cells in the Management of Non-Hodgkin Lymphoma 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Speaker and Chair: Oral Session 3: Cell and Gene Therapy 1. 
  Milan, Italy - 1/31/2014
• Invited Speaker: “T cell Therapies for Hematologic Malignancies Without Gene Transfer”. 
  Paris, France - 1/26/2014
• “T cell Therapies for Viral Infections and Cancer: Broadening Applicability” 
  Ottawa, Canada - 1/25/2014
• “T-cell Therapies for EBV+ Lymphomas - Where have we come from and where are we going?” 
  University of Pennsylvania, Philadelphia, PA - 1/15/2014
• “T-cell Therapies for Leukemia and Lymphoma – Broadening Applicability” 
  Johns Hopkins University, Baltimore, MD - 1/15/2014
• "Virus specific T cells after HSCT: Broadening applicability” 
  The Bronx, NY - 1/12/2014
• Virus Specific T-cell Therapy Post Transplant - Broadening Applicability. 
  Blatimore, MD - 1/12/2014
• Cell Therapies for Infection, Inflammation and Cancer: Broadening Applicability. 
  Children’s National Medical Center. Washington, DC - 1/12/2014
• Invited Speaker: “T-cell therapies targeting Viruses and Cancer without GVHD”. 
  NIH Cloisters, Building 60, Bethesda, MD - 1/10/2014
• “T cell Therapies for EBV+ Lymphomas”. 
  Berlin, Germany - 1/9/2014
• How to Build a Successful Research Team. 
  Bethesda, MD - 1/6/2014
• “Cell Therapy for Cancer”. 
  Palm Beach, FL - 1/6/2014
• “T cell therapies for Hematologic Malignancies”. 
  BC Cancer Center. Vancouver, Canada - 1/31/2013
• “T-cell Therapies for EBV-associated Lymphomas.” 
  The Denton A. Cooley Auditorium, Houston, TX - 1/30/2013
• “T-cell Therapies for EBV Lymphomas”. 
  Vancouver, Canada - 1/30/2013
• “Virus specific T cell therapies”. 
  BC Children’s Hospital, UBC - 1/29/2013
• “Engineering Viral Specific T Cells from Cord Blood Grafts”. 
  1/27/2013
• Invited speaker: How to submit an IND. 
  Fort Myers, FL - 1/17/2013
• “State of the Science- Pediatric Lymphoma”. 
  Abu Dhabi, United Arab Emirates - 1/16/2013
• “T-cells therapies for Leukemia and Lymphoma”. 
  Abu Dhabi, United Arab Emirates - 1/16/2013
• Join now to see all

Other

• "Ask the Doctor About Lymphoma" Program 
  Houston Chapter of the Lymphoma Research Foundation
  Houston, TX - 1/24/2009
• Pac-Man' cancer treatment underway in Houston. 
  ABC Channel 13
  http://abclocal.go.com/ktrk/video?id=7174696
  1/16/2009
• Leukemia Lymphoma Society enews line 
  
  http://www.leukemia-lymphoma.org/eMarketing/eNewsArchives/eNewsline/2009/March.htm
  1/1/2009
• Fight the Good Fight. 
  Texas Children’s Hospital Magazine
  https://waystogive.texaschildrens.org/NetCommunity/Document.Doc?id=236
  1/1/2009
• The Leukemia and Lymphoma Society and Texas Children’s Hospital cordially invite you to attend an Educational Program A Look into Pediatric Blood Cancers:“Childhood Ca... 
  
  Houston, TX - 1/23/2008
• Immunotherapeutic options for non-Hodgkin's lymphoma and Hodgkin's disease. 
  Kennedy-Nasser AA, Bollard CM, Touch Briefings, US Oncological Disease 2007 - Issue II
  1/1/2007
• Science Advances: Triple Killer. Physicians create new cells to stave off common viruses that threaten transplant patients. 
  NCRR Reporter
  http://www.ncrr.nih.gov/newspub/Winter07rpt/stories4.asp
  1/1/2007
• Three-in-one Virus Killer Prevents Common, Often Fatal Infections 
  Science Daily
  http://www.sciencedaily.com/releases/2006/10/061026185056.htm
  1/27/2006
• By Ruth SoRelle, M.P.H. ”Catherine Bollard takes center stage in fighting disease” 
  Baylor College of Medicine, "From the Laboratories"
  http://www.txccc.org/content.cfm?content_id=1344
  1/1/2006
• Ernst Schering Research Foundation Workshop, Chapter 8 
  Brenner MK, Bollard CM, Huls MH, Gottschalk S, Heslop HE, Rooney CM
  1/1/2004
• Participation in regular reviews submitted to TXCCC’s International eJournal 
  
  http://www.texaschildrenshospital.org/CareCenters/Cancer/Perspectives/Poplack.html
• Patent Application OTA#01-094; “Adopting a TGFB-related TumorProtection Strategy to Enhance Anti-Tumor Immunity” 
  Catherine M Bollard and Cliona M Rooney
• Join now to see all